Performance

MAZE +22.06%

Watchlist

Select an item

RETURNS	1D	YTD	1Y	5Y Ann.	Max DD	Sharpe	Div. Yield
MAZE	+2.11%	-15.74%	+22.06%	—	-56.81%	0.60	0.00%

Summary

MAZE at a glance

MAZE returned +22.06% over the past year. Its worst drop in that year was -56.81%, smaller than 15% of stocks on Redstone, and its Sharpe ratio of 0.60 beats 55% of stocks on Redstone. It pays no dividends.

Ranking

How MAZE ranks

Current Drawdown

-32.65%

Rolling Volatility

57.64%

Actions

Metrics

Risk Indicators

Alpha32.68%

Beta0.78x

Sharpe0.60

Sortino0.85

Omega1.13

Calmar0.39

Martin1.08

Profile

About MAZE

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity.

Sector: Health Care
Industry: Biological Products, (no Diagnostic Substances)
Market cap: $1.9B
Listed: Jan 2025
Employees: 141
Headquarters: South San Francisco, CA
Website: mazetx.com

Comparisons

MAZE: Maze Therapeutics, Inc.

MAZE at a glance

How MAZE ranks

Current Drawdown

Rolling Volatility

About MAZE

Related comparisons